Although the FDA has not yet awarded the title of interchangeable to any biosimilar, legislation that governs their substitution will continue to be a dominant state issue in 2017. Since 2013, 24 states and Puerto Rico have passed legislation regarding interchangeable biologics. As many as 15 states will have biosimilar-related legislation introduced by coalitions in…
![](https://www.the-rheumatologist.org/wp-content/uploads/2016/11/THR_Nov_2016_pp15_01-150x150.jpg)